Oncology Division
John F. DiPersio

John F. DiPersio, MD, PhD

Department of Medicine
Oncology Division
Bone Marrow Transplantation & Leukemia
Stem Cell Biology
Department of Pediatrics
Department of Pathology & Immunology

Clinical Interests

  • Allogeneic stem cell transplantation
  • Haploidentical stem cell transplantation

Research Interests

  • Hematopoietic growth factor receptors
  • Murine models of graft-versus-host disease and graft-versus-leukemia
  • Leukemia genomics


  • 314-454-8306 (office)
  • 314-454-7551 (fax)
  • Division of Oncology
    Campus Box 8007
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)
  • 626 Southwest Tower (lab)


My research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking and clinical and translational programs in both leukemia/MDS and stem cell transplantation. My laboratory also utilizes unique mouse models of allogeneic stem cell transplantation to explore novel genetic and epigenetic interventions aimed at mitigating graft vs. host disease (GvHD) while maintaining graft vs. leukemia (GvL). I am also a PI of multiple clinical trials focused on the diagnosis and treatment of patients with hematologic malignancies or those undergoing allogeneic stem cell transplantation. As Deputy Director of the Siteman Cancer Center I oversee all clinical and basic science research in the cancer center and I am active as a mentor of trainees and junior faculty and oversee faculty recruitment and retention in the Division. My personal research has focused on the role of stem cell transplantation and novel targeted interventions to alter the natural history of AML and other hematological malignancies. These studies have utilized bench-to-bedside mechanistic and preclinical modeling studies followed by early phase clinical trials. They have focused on targeting key elements of the hematopoietic niche for optimal stem cell mobilization and chemosensitization, mitigating GvHD in T replete transplants, understanding the genomic alterations in de novo and relapsed AML and developing and testing in the clinic novel therapeutics and immunotherapeutics for the treatment of AML before and after stem cell transplantation.


Targeting leukemic stem cells using immunotherapy


Targeting hematopoietic niche